

THE PARTIAL RESPONSE TO FIRST GENERATION SOMATOSTATIN

ANALOGUES GUIDES THE CHOICE AND MAY PREDICT THE OUTCOME OF SECOND LINE THERAPIES WITH PASIREOTIDE LAR: DATA FROM A REAL LIFE EXPERIENCE

SARA MENOTTI, SABRINA CHILOIRO, DENISE COSTA, ROSA LAURETTA, VALERIA MERCURI, EMILIA SBARDELLA, IRENE SAMPERI, MARIALUISA APPETECCHIA, ANTONELLA GIAMPIETRO, PATRIZIA GARGIULO, ANDREA M ISIDORI, MAURIZIO POGGI, LAURA DE MARINIS, ALFREDO PONTECORVI, ANTONIO BIANCHI.

INTRODUCTION


The treatment of acromegaly resistant to first generation somatostatin analogues (first gen-SSA) is often difficult. The aim of this study is to investigate the role of partial response and resistance to first gen-SSA in the choice of second line treatments.

MATERIALS AND METHODS


A retrospective and multicenter study was conducted on 100 SSA-resistant acromegaly patients and treated with Pasireotide Lar (Pasi-Lar), Peg-V in monotherapy (m-Peg-V) or in combination with first gen-SSA (c-Peg-V).

RESULTS

Thirty-three patients (33%) were treated with m-Peg-V, 36 (36%) with c-Peg-V and 31 with Pasi-Lar (31%). According to logistic regression, m-Peg-V was chosen in older patients ($p=0.01$) with not-invasive adenomas ($p=0.009$), c-Peg-V therapy in younger patients ($p=0.001$) with invasive adenomas ($p=0.02$), Pasi-Lar was in invasive adenomas ($p=0.01$) and in patients partially responsive to first-gen SSA ($p=0.01$). The last follow-up, 68 patients (68%) reached the acromegaly control: 22 with m-Peg-V (32.4%), 23 with c-Peg-V (33.8%) and 23 with Pasi-Lar (33.8%). Patients non-responsive to c-Peg-V had higher IGF-I levels (median $3.2 \times \text{ULN}$, IQR: 1.6, $p<0.001$) and required higher Peg-V dosage (median 30 mg/daily IQR: 10, $p=0.002$) as compared to responsive patients (median IGF-I $\times \text{ULN}$: 2.1 IQR: 1.4; median Peg-V dosage 20 mg/daily IQR: 10). All patients responsive to Pasi-Lar were partially responsive to first gen-SSAs ($p=0.02$).



HISTOGRAM REPRESENTING THE RATE OF PARTIAL CONTROL AND RESISTANCE OF FIRST GENERATION SSA ACCORDING TO THE CHOICE OF DIFFERENT SECOND LINE TREATMENTS (M-PEG-V, C-PEG-V AND PASIREOTIDE LAR). UNIVARIATE ANALYSIS



HISTOGRAM REPRESENTING THE RATE OF PATIENTS REACHED THE ACROMEGALY CONTROL, ACCORDING TO THE PARTIAL RESPONSE OR RESISTANCE OF FIRST GENERATION SSA. UNIVARIATE ANALYSIS

DISCUSSION AND CONCLUSION

Our data showed that c-Peg-V and Pasi-Lar are chosen for the treatment of invasive tumors. The partial response to first gen-SSA seems to be the main determinant for the choice of Pasi-Lar and positively predicts the treatment outcome.